Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet™ or in vivo-jetPEI^® induces enhanced serological, cellular and protective immune responses

References

• Abbas AK, Murphy KM, Sher A. (1996). Functional diversity of helper T lymphocytes. Nature 383:787–93.
   PubMed Web of Science ®Google Scholar
• Adams JR, Haughney SL, Mallapragada SK. (2015). Effective polymer adjuvants for sustained delivery of protein subunit vaccines. Acta Biomater 14:104–14.
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Schur PH, MacDonald NE, Steinman L. (2014). Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 50:1–11.
   PubMed Web of Science ®Google Scholar
• Cao W, Davis WG, Kim JH, et al. (2016). An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice. Nanomedicine 12:1909–17.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). (1997). Isolation of avian influenza A(H5N1) viruses from humans–Hong Kong, May-December 1997. MMWR Morb Mortal Wkly Rep 46:1204–7.
   PubMedGoogle Scholar
• Di Gioia S, Conese M. (2009). Polyethylenimine-mediated gene delivery to the lung and therapeutic applications. Drug Des Devel Ther 2:163–88.
   PubMedGoogle Scholar
• FDA. (2007). FDA approval letter - influenza virus vaccine, H5N1. Rockville, MD, 2007 [April 17]. Available at: https://www.drugs.com/newdrugs/fda-approves-first-u-s-vaccine-humans-against-avian-influenza-virus-h5n1-442.html [last accessed 28 Feb 2018].
   Google Scholar
• FDA. (2013). FDA approval letter - influenza A (H5N1) virus monovalent vaccine, adjuvanted. 2013 [Nov 22]. Available at: https://www.drugs.com/newdrugs/fda-approves-first-adjuvanted-vaccine-prevention-h5n1-avian-influenza-3972.html [last accessed 28 Feb 2018.].
   Google Scholar
• FDA. (2015). FDA approves first seasonal influenza vaccine containing an adjuvant. Available at: https://www.medscape.com/viewarticle/855000 [last accessed 28 Feb 2018.].
   Google Scholar
• Gao R, Cao B, Hu Y, et al. (2013). Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368:1888–97.
   PubMed Web of Science ®Google Scholar
• Giesecke C, Frolich D, Reiter K, et al. (2014). Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells. J Immunol 192:3091–100.
   PubMed Web of Science ®Google Scholar
• Guy B, Pascal N, Francon A, et al. (2001). Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19:1794–805.
   PubMed Web of Science ®Google Scholar
• Hirahara K, Nakayama T. (2016). CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Intimm 28:163–71.
   PubMed Web of Science ®Google Scholar
• Jones EN, Amoah S, Cao W, et al. (2017). An adjuvanted A(H5N1) subvirion vaccine elicits virus-specific antibody response and improves protection against lethal influenza viral challenge in mouse model of protein energy malnutrition. J Infect Dis 216(Suppl. 4):S560–S5.
   Web of Science ®Google Scholar
• Kulkarni RR, Rasheed MA, Bhaumik SK, et al. (2014). Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J Virol 88:13990–4001.
   PubMed Web of Science ®Google Scholar
• Layton RC, Gigliotti A, Armijo P, et al. (2011a). Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret. PLoS One 6:e20641.
   PubMed Web of Science ®Google Scholar
• Layton RC, Petrovsky N, Gigliotti AP, et al. (2011b). Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 29:6242–51.
   PubMed Web of Science ®Google Scholar
• Leist TP, Cobbold SP, Waldmann H, et al. (1987). Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol 138:2278–81.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Concepcion RJ, Ahmed R. (1994). CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68:8056–63.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Cherwinski H, Bond MW, et al. (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–57.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Sad S. (1996). The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138–46.
   PubMedGoogle Scholar
• Pack DW, Hoffman AS, Pun S, Stayton PS. (2005). Design and development of polymers for gene delivery. Nat Rev Drug Discov 4:581–93.
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Pyungporn S, Prachayangprecha S, Makkoch J. (2013). Global alert to avian influenza virus infection: from H5N1 to H7N9. Pathog Glob Health 107:217–23.
   PubMed Web of Science ®Google Scholar
• Qin T, Yin Y, Huang L, et al. (2015). H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice. Clin Vaccine Immunol 22:421–9.
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. (2013). Key roles of adjuvants in modern vaccines. Nat Med 19:1597–608.
   PubMed Web of Science ®Google Scholar
• Sanchez V, Gimenez S, Haensler J, et al. (2001). Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol Med Microbiol 30:157–65.
   PubMedGoogle Scholar
• Shi W, Shi Y, Wu Y, et al. (2013). Origin and molecular characterization of the human-infecting H6N1 influenza virus in Taiwan. Protein Cell 4:846–53.
   PubMed Web of Science ®Google Scholar
• Sridhar S. (2016). Heterosubtypic T-cell immunity to influenza in humans: challenges for universal T-cell influenza vaccines. Front Immunol 7:195.
   PubMed Web of Science ®Google Scholar
• Wegmann F, Gartlan KH, Harandi AM, et al. (2012). Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol 30:883–8.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2017). Influenza: cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. Available at: http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/ [last accessed 01 Dec 2017].
   Google Scholar
• Yang ZF, Mok CK, Peiris JS, Zhong NS. (2015). Human infection with a novel avian influenza A(H5N6) virus. N Engl J Med 373:487–9.
   PubMed Web of Science ®Google Scholar
• Zhang T, Bi Y, Tian H, et al. (2014). Human infection with influenza virus A(H10N8) from live poultry markets, China, 2014. Emerg Infect Dis 20:2076–9.
   PubMed Web of Science ®Google Scholar